Phase 2 N=98 A Study of A-101 Solution in Subjects With Common Warts.
Common Warts
Primary: Efficacy Based on Mean Change in Physician Wart Assessment Over Time — -0.38; -1.00; -0.44 units on a scale — p=0.555
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=124 Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
Atopic Dermatitis
Primary: The Number of Patients in Each Treatment Group That Have Clinical Success — 21; 27 Participants — p=0.3353
Phase 2 N=172 Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
Seborrheic Keratosis
Primary: Mean Per Subject Percentage Target Lesions Judged Clear by the Physician's Lesion Assessment (PLA) — 4.82; 26.79; 45.09 percentage of lesions cleared — p=0.0003
Phase 2 N=28 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
Atopic Dermatitis
Primary: The Number of Patients in the Study With HPA Axis Suppression — 8; 9 Participants
Phase 2 N=130 Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery
Atrial Fibrillation
Primary: Time to In-hospital Post-operative Atrial Fibrillation (POAF) — 224.38; 194.76 hours — p=0.18
Phase 4 N=20 Study of Effects of Sildenafil on Patients With Fontan Heart Circulation
Single Ventricle Heart Disease After Fontan Surgery
Primary: End-systolic Elastance — 0.85; 1.8 Ees in mmHg/ml/m2
Phase 2 N=26 Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants With HPA Axis Suppression — 3; 0; 21; 1 Participants
Phase 3 N=543 Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin) — -1.48; -1.40 percentage of HbA1c — p=0.2430
N/A N=376 Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease
Degenerative Disc Disease
Primary: Overall Success at 24 Months Relative to Baseline — 42.2; 28.3; 61.9; 52.8 percentage of participants — p=<0.05
Phase 3 N=427 Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Squamous Cell Carcinoma, Non-Small-Cell Lung
Primary: Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance — 3.12; 2.60 months — p=0.3486
Phase 3 N=806 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects Reporting Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) — 31; 6; 30; 13 Participants
N/A N=20 Effect of tACS Stimulation on Alpha Oscillations
Healthy
Primary: Salivary Alpha Amylase — 0.00695; 0.03055 log-normalized percent change of U/mL — p=0.70
Phase 3 N=290 A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers
Fever
Primary: Time Weighted Sum of Temperature Difference (WSTD) From 0 to 8 Hours — 9.28; 12.54; 11.09; 12.39 degrees fahrenheit — p=0.002
Phase 3 N=258 Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
Hyperkalemia
Primary: Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population). — 5.0603; 4.7544; 4.5081; 4.3742 mmol/L
Phase 2 N=20 Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
IgG4-RD
Primary: Proportion of Patients With an Improvement in IgG4-RD Activity — 12; 4; 2; 0 Participants